Chemotherapy Plus Lapatinib or Trastuzumab or Both in Her2+ Primary Breast Cancer. A Randomized Phase IIb Study With Biomarker Evaluation

Trial Profile

Chemotherapy Plus Lapatinib or Trastuzumab or Both in Her2+ Primary Breast Cancer. A Randomized Phase IIb Study With Biomarker Evaluation

Completed
Phase of Trial: Phase II

Latest Information Update: 13 May 2016

At a glance

  • Drugs Lapatinib (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel; Trastuzumab
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms CHER-LOB
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 May 2016 Results of pooled sub-group analysis assessing PIK3CA mutations from GeparQuattro, GeparQuinto, GeparSixto, NeoALTTO and CHERLOB trials (n=967) published in the Annals of Oncology
    • 03 Mar 2014 Results published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top